Glenmark Pharmaceuticals Gains 2.25%: 3 Key Factors Driving the Week’s Resilience

9 March: Weak Start Amid Broader Market Sell-Off

Glenmark Pharmaceuticals began the week on a subdued note, closing at Rs.2,116.85, down 0.25% from the previous Friday’s close. This modest decline came as the Sensex tumbled 1.91%, reflecting widespread market weakness. Trading volume was relatively low at 7,770 shares, indicating cautious investor sentiment ahead of anticipated developments later in the week.

10 March: Strong Intraday Rally and Surge in Call Option Activity

The stock rebounded sharply on 10 March, surging 5.26% to close at Rs.2,228.25. Glenmark hit an intraday high of Rs.2,225, marking a 5.08% gain on the day and significantly outperforming the Sensex, which rose 1.30%. This rally was supported by a remarkable surge in call option activity, with 7,917 contracts traded at the Rs.2,200 strike price for the 30 March expiry, generating a turnover of ₹1,919.08 lakhs. The open interest of 757 contracts at this strike price underscored strong bullish positioning among traders.

Technically, the stock traded above all key moving averages, reinforcing its positive momentum. Despite a 47.32% drop in delivery volumes on 9 March, liquidity remained robust, enabling sizeable trades. Glenmark’s Mojo Score stood at 78.0 with a Buy rating, reflecting solid fundamentals amid a volatile market backdrop.

11 March: New 52-Week High Amid Strong Financials

Glenmark Pharmaceuticals continued its upward trajectory on 11 March, reaching a new 52-week high of Rs.2,297.20 during intraday trading. The stock closed at Rs.2,272.50, up 1.99% on the day, outperforming the Sensex which declined 1.36%. This marked a cumulative gain of 7.84% over two days, highlighting strong investor confidence despite a challenging market environment.

Financially, the company reported net sales of Rs.9,947.49 crores for the latest six-month period, growing 45.83%, with profit after tax rising substantially to Rs.2,026.77 crores. Return on capital employed stood at 35.65%, and return on equity at 23.5%, indicating efficient capital utilisation. The conservative debt profile, with a Debt to EBITDA ratio of 0.89 times, further strengthened the company’s creditworthiness.

Institutional investors hold a significant 39.33% stake, reflecting strong backing. Glenmark ranks in the top 1% of companies rated by MarketsMOJO, positioned 10th in the mid-cap segment and 32nd overall, underscoring its market stature. The Mojo Grade remains Buy, adjusted from Strong Buy in June 2025, reflecting a recalibrated but positive outlook.

12 March: Minor Correction Amid Market Weakness

On 12 March, the stock experienced a slight pullback, closing at Rs.2,258.00, down 0.64%. This modest decline occurred alongside a 0.66% drop in the Sensex, signalling broader market pressures. Trading volume decreased to 13,446 shares, suggesting some profit-taking after the recent rally. Despite this, Glenmark remained well above key moving averages, maintaining its technical strength.

13 March: Week Ends with Decline Amid Broader Market Sell-Off

The week concluded on a cautious note as Glenmark Pharmaceuticals fell 3.90% to close at Rs.2,170.00. This decline was sharper than the Sensex’s 2.29% drop, reflecting intensified selling pressure across the market. Volume increased to 29,687 shares, indicating active trading. Despite the setback, the stock’s weekly gain of 2.25% contrasted favourably with the Sensex’s 4.87% loss, underscoring Glenmark’s relative resilience.

Key Takeaways

Positive Signals: Glenmark Pharmaceuticals demonstrated notable resilience by gaining 2.25% over the week while the Sensex declined 4.87%. The stock’s intraday highs on 10 and 11 March, including a new 52-week peak at Rs.2,297.20, reflect strong technical momentum supported by robust fundamentals and institutional backing. Elevated call option activity at the Rs.2,200 strike price signals bullish sentiment among traders ahead of the March expiry.

Cautionary Notes: The decline in delivery volumes and the pullback on 12 and 13 March suggest some profit-taking and caution among long-term holders. The broader market weakness, with the Sensex falling for three consecutive weeks, poses headwinds that could impact near-term price action. Mixed technical indicators such as mildly bearish KST signals on monthly charts warrant monitoring for potential shifts in momentum.

Conclusion

Glenmark Pharmaceuticals Ltd. navigated a volatile market week with relative strength, closing higher by 2.25% against a sharply falling Sensex. The stock’s performance was underpinned by strong intraday rallies, a new 52-week high, and significant call option interest, reflecting positive investor sentiment and solid fundamentals. While the week ended with some profit-taking amid broader market declines, Glenmark’s sustained outperformance and robust financial metrics position it as a resilient player within the Pharmaceuticals & Biotechnology sector. Investors should continue to watch technical signals and market trends closely as the March expiry approaches.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today